X0202 SCHEDULE 13G 0002043476 XXXXXXXX LIVE Common Stock, $0.0001 par value 10/13/2026 0002002988 Retension Pharmaceuticals, Inc. 76135H100 1104 West Broad Street #1029 , Falls Church VA 22046 Rule 13d-1(c) The B Group, Inc. KS 0.00 833333.00 0.00 833333.00 833333.00 N 10.00 IA HC B Group Capital LLC DE 0.00 833333.00 0.00 833333.00 833333.00 N 10.00 OO Branden B. Muhl X1 0.00 833333.00 0.00 833333.00 833333.00 N 10.00 HC IN Retension Pharmaceuticals, Inc. 1104 West Broad Street #1029, Falls Church, Virginia 22046 Each of the following is hereinafter individually referred to as a "Reporting Person" and collectively as the "Reporting Persons." This statement is filed on behalf of: The B Group, Inc. B Group Capital LLC Branden B. Muhl The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G. The principal business address of The B Group, Inc. is 2900 McKinnon Street, Suite 1101, Dallas, Texas 75201. The principal business address of each of B Group Capital LLC and Mr. Muhl is c/o The B Group, Inc., 2900 McKinnon Street, Suite 1101, Dallas, Texas 75201. The B Group, Inc. is organized under the laws of the State of Kansas. B Group Capital LLC is organized under the laws of the State of Delaware. Branden B. Muhl is a citizen of the United States. Y The information required by Item 4(a) is set forth in Row 9 of the cover page for each Reporting Person and is incorporated herein by reference. This Schedule 13G relates to 833,333 shares of Common Stock held by B Group Capital LLC. The B Group, Inc. serves as investment adviser to B Group Capital LLC. Mr. Muhl is the controlling person and manager of The B Group, Inc. and B Group Capital LLC, respectively. In such capacities, The B Group, Inc. and Mr. Muhl may each be deemed to beneficially own the shares of Common Stock held by B Group Capital LLC. The information required by Item 4(b) is set forth in Row 11 of the cover page for each Reporting Person and is incorporated herein by reference. Ownership percentages are based on 8,331,599 shares of the Issuer's Common Stock outstanding immediately after giving effect to the completion of the Issuer's initial public offering, as reported in the Prospectus Supplement filed pursuant to Rule 424(b)(4) by the Issuer with the Securities and Exchange Commission on October 9, 2026. The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each Reporting Person and is incorporated herein by reference. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Exhibit 99: Joint Filing Agreement The B Group, Inc. /s/ Branden B. Muhl 10/16/2026 B Group Capital LLC /s/ Branden B. Muhl 10/16/2026 Branden B. Muhl /s/ Branden B. Muhl 10/16/2026